Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

OCC Bulletin August 25, 2004	Final Rule Implementing Check Clearing for the 21st Century Act On July 26, 2004, the Federal Reserve Board released final amendments to Regulation CC and its commentary to implement the Check Clearing for the 21st Century Act, which was enacted on October 28, 2003, and becomes effective on October 28, 2004.
Bank Systems & Technology August 31, 2004 Cynthia Ramsaran	A Brave New World As banks prepare for the final push toward Check 21, they must overcome several roadblocks to succeed in the electronic age.
Bank Systems & Technology December 1, 2005 Maria Bruno-Britz	Check 21: Evolution, Not Revolution Originally hailed by legislators as ushering in a new era of banking, it seems the reality of Check 21 is a bit less lofty than they anticipated - so far, at least.
The Motley Fool October 13, 2004 Selena Maranjian	Bye-Bye, Canceled Checks New "Check 21" rules may soon be changing how your bank serves you.
Bank Technology News January 2005 Michael Sisk	The Post-October 28 World: It's Time for a Reality Check on Check 21 Believe it or not, there are still many misconceptions about the law among the public, which banks must battle as they gradually implement new checking technology.
Bank Technology News March 2007 Glen Fest	Image Exchange: Imaging: Are Happy Days Here at Last? Image-cleared checks have exceeded substitute items, and are expected to surpass paper-check volume by the end of the year.
Bank Systems & Technology May 6, 2004 Judy Ward	Banks Prepare Returns Processing for Check 21 Electronic check processing will speed transactions, cut costs and fight fraud.
U.S. Banker June 2003 Robert Kapler	Getting Serious About Check 21-Finally The average check is handled 12 times, so check image technology could sharply reduce error rates. But choosing a system depends on a bank's specific needs.
U.S. Banker May 2002 Mark Bruno	Digital Imaging Picks Up Steam Banks across the nation suddenly are working very hard to implement the long-promised technology of check imaging...
The Motley Fool April 25, 2007 Mary Dalrymple	Hey, Give Me My Money! Fewer check processing sites means that, for consumers, more deposit checks get categorized as "local." That means more of your checks must be deposited under the two-day rule instead of the five-day rule.
Bank Technology News December 2002 Glen Fest	Picking Up An Expensive Check The proposed Check Clearing for the 21st Century Act, or Check 21, will be costly, especially for community banks.
The Motley Fool January 28, 2005	How to Avoid Breaking the Bank Why pay more than you need to -- to your bank, of all things?
BusinessWeek June 10, 2010 Robert Schmidt	Wall Street Can't Beat Its Nemesis at Treasury In talks with banks over regulation, assistant Treasury secretary Michael Barr has stayed tough.
The Motley Fool August 9, 2007 Brian Orelli	Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
Bank Systems & Technology February 10, 2004 Jim Eckenrode	The More Things Change... For big banks, retail's over half the pie.
The Motley Fool February 28, 2007 Brian Lawler	Barr's Becoming Big Generic drug producer Barr Pharmaceuticals announces its first quarterly earnings numbers after acquiring Pliva. Investors, take note.
The Motley Fool June 25, 2008 Brian Orelli	An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets.
The Motley Fool August 8, 2008 Rich Duprey	Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
The Motley Fool June 27, 2006 Stephen D. Simpson	Barr Bulks Up For Barr Labs, buying Pliva adds manufacturing capabilities, market opportunities, and pipeline candidates. Investors, take note.
The Motley Fool December 17, 2007 Brian Orelli	Barr Labs' Legal Tables Turned Barr Labs announces that is suing both Watson Pharmaceuticals and Novartis' generic subsidiary Sandoz for patent infringement regarding Barr's SEASONALE extended-cycle birth control pill.
Reason March 2007 David Weigel	Bob Barr and the Libertarians A former Republican congressman joins a third party.
The Motley Fool July 16, 2007 Brian Orelli	Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price.
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool June 30, 2006 Stephen D. Simpson	Barr Labs and Pliva: Round 2 The Croatian generic drugmaker is now a hot property, as a previously spurned bidder, Icelandic generics firm Actavis, refuses to let Barr Labs win this battle yet. Investors, take note.
The Motley Fool September 11, 2006 Brian Lawler	Barr's Bidding War Barr Pharmaceuticals takes a big bite of the booming generics market. Investors, take note.
Reason December 2003 Jesse Walker	Bob Barr, Civil Libertarian Representing the right wing of the ACLU, Barr represents a set of conservatives' growing discomfort with the Bush administration's erosion of individual liberty.
The Motley Fool June 27, 2008 Brian Orelli	Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out.
Bank Systems & Technology June 1, 2005	New Products: Carreker Catches Double IRDs, and more Carreker launched a duplicate image replacement document protection solution... Metavante Suite Offers Interoperability... IntegraSys Wire Transfer Solution...
BusinessWeek January 10, 2005 Mara Der Hovanesian	Barr: A No-Name Star More than $30 billion in patents will elapse by the end of 2007, which spells new potential for generics such as Barr Pharmaceuticals. With Barr's solid pipeline, the stock, at $46, is a bargain.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
The Motley Fool September 8, 2005 Stephen D. Simpson	Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either.
The Motley Fool May 4, 2006 Stephen D. Simpson	A More Realistic Bar for Barr Labs An unpleasant, but not altogether unexpected drop makes this generic drug company and better value for investors.
U.S. Banker April 2002	Tougher On The Big Boys Being bigger is not necessarily better for corporations seeking loans from their banks. A study by the Association for Financial Professionals indicates that banks are putting heavy pressure on their biggest borrowers to throw more business the banks' way. Or else: No credit...
The Motley Fool November 12, 2007 Brian Orelli	Raising the Barr Barr Pharmaceuticals' acquisition of Pliva increases sales, but it doesn't help raise the bottom line. Investors, take note.
Bank Systems & Technology June 26, 2006 Maria Bruno-Britz	Lands of Opportunity The international opportunities for U.S. banks with the right IT and know-how can be huge, provided they follow the appropriate strategy.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.
InternetNews September 18, 2006 Sean Michael Kerner	Red Hat Stacks The Deck Red Hat stacks both LAMP and J2EE 100 days after acquiring JBoss.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.
The Motley Fool August 15, 2006 Stephen D. Simpson	Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence.